Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia

Nature Reviews Drug Discovery

Volumn 3, Issue 4, 2004, Pages 353-359

  Roth, Bryan L ^a   Sheffer, Douglas J ^a   Kroeze, Wesley K ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; FLUOXETINE; HALOPERIDOL; LITHIUM; MEPROBAMATE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; ZIMELDINE; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; MOLECULAR INTERACTION; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; WEIGHT GAIN;

EID: 4644271084     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1346     Document Type: Review

References (63)

1. Shorter, E. Looking backwards: a possible new path for drug discovery in psychopharmacology. Nature Rev. Drug Discov. 1, 1003-1006 (2002).
2. Carlsson, A. & Wong, D. T. Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 61, 1203 (1997).
3. Hippius, H. A historical perspective of clozapine. J. Clin. Psychiatry 60 (Suppl. 12), 22-23 (1999).
4. Harrison, P. J. & Owen, M. J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361, 417-419 (2003).
5. Lewis, C. M. et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet. 73, 34-48 (2003).
6. Setola, V. & Roth, B. L. Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. Mol. Pharmacol. 64, 1277-1278 (2003).
7. Coyle, J. T. & Duman, R. S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157-160 (2003).
8. Roth, B., Sheffler, D. J. & Potkin, S. Atypical antipsychotic drugs: unitary or multiple mechanisms for 'atypicality'. Clin. Neurosci. Res. (in the press).
9. Kane, J., Honigfield, G., Singer, J., Meltzer, H. Y. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789-796 (1988).
10. Meltzer, H. Y. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82-91 (2003).
11. Colpaert, F. C. Discovering risperidone: the LSD model of psychopathology. Nature Rev. Drug Discov. 2, 315-320 (2003).
12. i values. J. Pharmacol. Exp. Ther. 251, 238-246 (1989).
13. 2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16, 517-525 (1986).
14. Leucht, S., Wahlbeck, K., Hamann, J. & Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581-1589 (2003).
15. Tuunainen, A., Wahlbeck, K. & Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr. Res. 56, 1-10 (2002).
16. Fontaine, K. R. et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 101, 277-288 (2001).
17. 1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519-526 (2003).
18. Meltzer, H. Y. & McGurk, S. R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233-255 (1999).
19. 2A receptors in working memory. J. Neurosci. 22, 2843-2854 (2002).
20. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41, 210-219 (2001).
21. 1 receptor stimulation. Science 287, 2020-2022 (2000).
22. 4 receptor antagonist. Trends Pharmacol. Sci. 18, 186 (1997).
23. 2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry 156, 419-425 (1999).
24. de Paulis, T. M-100907 (Aventis). Curr. Opin. Investig. Drugs 2, 123-132 (2001).
25. Meltzer, H., Arvantis, L., Bauer, D., Rein, W. & Group, M. S. A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry (in the press).
26. Rasmussen, T. et al. The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schiziphr. Res. 49, 193-201 (2001).
27. Clark, D. et al. Is 3-PPP a potential antip sychotic agent? Evidence from animal behavioral studies. Eur. J. Pharmacor. 83, 131-134 (1982).
28. Lahti, A. C. et al. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol. Psychiatry 43, 2-11 (1998).
29. 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J. Neural Transm. 105, 719-734 (1998).
30. Benkert, O., Muller-Siecheneder, F. & Wetzel, H. Dopamine agonists in schizophrenia: a review. Eur. Neuropsychopharmacol. 5, S43-S53 (1995).
31. 2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274, 329-336 (1995).
32. Kane, J. M. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin. Psychiatry 63, 763-771 (2002).
33. Inoue, T., Domae, M., Yamada, K. & Furukawa, T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3- dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277, 137-143 (1996).
34. 2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389 (2002).
35. Hemrick-Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002).
36. Lawler, C. P. et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20, 612-627 (1999).
37. Kenakin, T. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103-110 (2002).
38. Roth, B. L. & Chuang, D. M. Multiple mechanisms of serotonergic signal transduction. Life Sci. 41, 1051-1064 (1987).
39. Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411 (2003).
40. Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809 (2003).
41. Anderson, I. M. Meta-analytical studies on new antidepressants. Br. Med. Bull. 57, 161-178 (2001).
42. Thase, M. E., Entsuah, A. R. & Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234-241 (2001).
43. Briley, M. New hope in the treatment of painful symptoms in depression. Curr. Opin. Investig. Drugs 4, 42-45 (2003).
44. Zubenko, G. et al. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Am. J. Med Genet. 123B, 1-18 (2003).
45. Brunner, D., Nestler, E. & Leahy, E. In need of high-throughput behavioral systems. Drug Discov. Today 7, S107-S112 (2002).
46. Bohannon, J. Animal models. Can a mouse be standardized? Science 298, 2320-2321 (2002).
47. Amsterdam, J. D., Brunswick, D. J. & Hundert, M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A - a putative, new antidepressant. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 1333-1338 (2002).
48. Feighner, J. P. et al. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression. Int. Clin. Psychopharmacol. 16, 345-352 (2001).
49. Palfreyman, M. G. et al. Novel directions in antipsychotic target identification using gene arrays. Curr. Drug Target CNS Neurol. Disord. 1, 227-238 (2002).
50. Suessbrich, H., Waldegger, S., Lang, F. & Busch, A. E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385, 77-80 (1996).
51. Rothman, R. B. et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000).
52. Remington, G. & Kapur, S. SB-277011 GlaxoSmithKline. Curr. Opin. Investig. Drugs 2, 946-949 (2001).
53. 4 Dopamine Antagonist Group. Arch. Gen. Psychiatry 54, 567 (1997).
54. Gewirtz, G. R. et al. BMY14802, a σ receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10, 37-40 (1994).
55. Muller, M. J. et al. Antipsychotic effects and tolerability at the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res. 89, 275-280 (1999).
56. van Berckel, B. et al. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol. Psychiatry 40, 1298 (1996).
57. Evins, A. E., Amico, E., Posever, T. A., Toker, R. & Goff, D. C. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 56, 19-23 (2002).
58. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361, 799-808 (2003).
59. Stahl, S. M., Entsuah. R. & Rudolph, R. L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry 52, 1166-1174 (2002).
60. Perez, V., Gilaberte, I., Faries, D., Alvarez, E. & Artigas, F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349, 1594-1597 (1997).
61. Berman, R. M. et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry 45, 1170-1177 (1999).
62. Nichols, D. E. Hallucinogens. Parmacol. Ther. 101, 131-181 (2004).
63. Kroeze, W. K., Sheffler, D. J. & Roth, B. L. G-protein-coupled receptors at a glance. J. Cell Sci. 116, 4867-4869 (2003).